ArteraAI vs Valar Labs (2026)
Both extract prognostic and predictive signal from routine H and E slides, and both hold grade A clinical evidence, which is rare, so the two diverge almost entirely on regulatory standing and where their evidence lives. If your failure mode is deploying a test a payer will not cover or a guideline panel has not vetted, start with ArteraAI, which holds FDA De Novo authorization, NCCN guideline inclusion, and CMS coverage, the most complete standing in the index. If you need a prognostic in bladder cancer, or a test orderable today as a send out without waiting on device clearance, start with Valar Labs, accepting the laboratory developed test evidentiary bar. Their strongest evidence sits in different cancers, so they compete directly only on prostate.
- The most complete regulatory and guideline standing in the index: FDA De Novo authorization in August 2025, inclusion in the NCCN prostate cancer guidelines as the first and only AI risk stratification tool, and CMS coverage with an established payment rate.
- Predictive, not only prognostic: for NCCN intermediate risk patients it estimates whether adding androgen deprivation therapy to radiation will help, described in the literature as the first predictive biomarker for that decision.
- A model a clinician can audit: locked at a stated version with fully enumerated inputs and published cut points tied to explicit ten year risk thresholds.
- The strongest evidence in a genuinely underserved cancer: multi center validation of its bladder assays in the Journal of Urology and European Urology, outperforming guideline based risk stratification across cohorts exceeding 1,000 patients on four continents, a decision ArteraAI does not address.
- Orderable today with no deployment: specimens are sent to Valar's own CLIA certified and CAP accredited laboratory and results return in days, so there is no platform to install.
- Checkable model supervision: more than 500,000 board certified pathologist annotations behind the platform, with effect sizes published plainly.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. ArteraAI and Valar Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | ArteraAI | Valar Labs |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | Not recorded | 2021 |
| Headquarters | Los Altos, California | Palo Alto, California, United States |
| Website | artera.ai | valarlabs.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards ArteraAI its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Valar Labs, ArteraAI grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Valar Labs its top capability grade on AI Centrality, Clinical and Operational Evidence and HIPAA and BAA Posture. Set against ArteraAI, Valar Labs does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Clinical and Operational Evidence and HIPAA and BAA Posture. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose ArteraAI or Valar Labs?
The AI Health Index grades ArteraAI higher than Valar Labs on every axis that separates them, several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Valar Labs does not grade higher on any scored axis.
Where do ArteraAI and Valar Labs differ most?
The widest separation the AI Health Index records between ArteraAI and Valar Labs is on Model Supply Chain Disclosure, where ArteraAI grades B and Valar Labs grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do ArteraAI and Valar Labs grade the same?
The AI Health Index grades ArteraAI and Valar Labs the same on several axes, including AI Centrality, Clinical and Operational Evidence and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have ArteraAI and Valar Labs not disclosed?
At the last review, at least one of ArteraAI and Valar Labs published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The two diverge most on regulatory route, and it governs adoption. ArteraAI is FDA cleared, guideline listed, and CMS covered; Valar reaches the clinic as a laboratory developed test under enforcement discretion, a lower evidentiary bar than clearance, and its Breakthrough Device Designation for the bladder test is a review pathway commitment, not a clearance.
Valar's coverage and reimbursement detail was not located, which for a laboratory developed test directly governs whether it is practically orderable. Neither publishes a security attestation, and Valar's specimen and result data reside with its own laboratory by design, a different risk profile rather than an absent one. ArteraAI's grid is assessed on seven axes rather than the full thirteen, so its security, PHI, and deployment posture were not evaluated.